Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist.

ABSTRACT: Metformin is currently considered a first-line therapy in type 2 diabetic patients. After issuing warnings for decades about the risks of lactic acidosis in patients with chronic nephropathy, metformin is now being re-evaluated. The most recent evidence from the literature has demonstrated both a low, acceptable risk of lactic acidosis and a series of favorable effects, which go beyond its hypoglycemic activity. Patients treated with metformin show a significant mortality reduction and lower progression towards end-stage renal disease in comparison with those treated with other hypoglycemic drugs. Concerning lactic acidosis, in the last few years it has been shown how lactic acidosis almost always developed when patients kept taking the drug in the face of a concomitant disease or situatio

SUBMITTER: Mariano F 

PROVIDER: S-EPMC8357762 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature